22 May 2013
Keywords: restrictions, pfizer, chantix, reports, neuropsych, aes, prompt
Article | 02 June 2008
New safety concerns on Pfizer's Chantix (varenicline) could slow the sales expansion of the smoking-cessation drug and land the world ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 June 2008
21 May 2013
© 2013 thepharmaletter.com